Pacira Pharmaceuticals (NASDAQ:PCRX) “Hold” Rating Reiterated Today By Canaccord Genuity; The Target Price is Set to $38.0

February 15, 2018 - By Adrian Mccoy

 Pacira Pharmaceuticals (NASDAQ:PCRX)

Investors sentiment decreased to 1.39 in Q3 2017. Its down 0.23, from 1.62 in 2017Q2. It fall, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported.

Moreover, Fmr Limited Liability Com has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 464,719 shares. Oak Ridge Invs Limited Liability Corp invested in 0.55% or 359,058 shares. Oppenheimer Asset Management Inc holds 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 7,375 shares. Geode Management Lc reported 416,675 shares. Legal General Gru Public Limited Co owns 19,662 shares. Elk Creek Prns Limited Co reported 612,049 shares stake. D Scott Neal Inc owns 200 shares for 0% of their portfolio. Point72 Asia (Hong Kong) accumulated 110 shares or 0% of the stock. Pnc Fincl Serv accumulated 7,770 shares or 0% of the stock. Da Davidson And Communications reported 12,728 shares. Bnp Paribas Arbitrage Sa has 4,763 shares. Metropolitan Life Insur Co Ny reported 0.01% stake. Bluecrest Capital Ltd holds 12,528 shares. Proshare Advsr Limited Co has invested 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Alphaone Investment Serv Llc reported 600 shares.

Since August 15, 2017, it had 0 buys, and 3 sales for $1.21 million activity. STACK DAVID M also sold $1.05M worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares. 3,461 shares valued at $127,192 were sold by Williams Kristen Marie on Tuesday, August 15. 1,044 shares were sold by HASTINGS PAUL J, worth $37,741.

Pacira Pharmaceuticals (NASDAQ:PCRX) Rating Reaffirmed

They currently have a $38.0 target price on Pacira Pharmaceuticals (NASDAQ:PCRX). The target price by Canaccord Genuity would suggest a potential upside of 5.26 % from the company’s current stock price. This has been revealed to investors in an analyst report on Wednesday morning.

Investors sentiment decreased to 1.39 in Q3 2017. Its down 0.23, from 1.62 in 2017Q2. It fall, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported.

Moreover, Fmr Limited Liability Com has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 464,719 shares. Oak Ridge Invs Limited Liability Corp invested in 0.55% or 359,058 shares. Oppenheimer Asset Management Inc holds 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 7,375 shares. Geode Management Lc reported 416,675 shares. Legal General Gru Public Limited Co owns 19,662 shares. Elk Creek Prns Limited Co reported 612,049 shares stake. D Scott Neal Inc owns 200 shares for 0% of their portfolio. Point72 Asia (Hong Kong) accumulated 110 shares or 0% of the stock. Pnc Fincl Serv accumulated 7,770 shares or 0% of the stock. Da Davidson And Communications reported 12,728 shares. Bnp Paribas Arbitrage Sa has 4,763 shares. Metropolitan Life Insur Co Ny reported 0.01% stake. Bluecrest Capital Ltd holds 12,528 shares. Proshare Advsr Limited Co has invested 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Alphaone Investment Serv Llc reported 600 shares.

Since August 15, 2017, it had 0 buys, and 3 sales for $1.21 million activity. STACK DAVID M also sold $1.05M worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares. 3,461 shares valued at $127,192 were sold by Williams Kristen Marie on Tuesday, August 15. 1,044 shares were sold by HASTINGS PAUL J, worth $37,741.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 10 Hold. Therefore 50% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $54.68’s average target is 51.47% above currents $36.1 stock price. Pacira Pharmaceuticals had 86 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Thursday, August 3 with “Market Perform”. Piper Jaffray maintained the shares of PCRX in report on Tuesday, February 13 with “Buy” rating. The firm has “Buy” rating given on Monday, November 20 by Wedbush. Piper Jaffray maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Wednesday, February 7 with “Buy” rating. The firm earned “Buy” rating on Tuesday, April 19 by Mizuho. The company was upgraded on Monday, August 21 by Janney Capital. The rating was maintained by RBC Capital Markets on Wednesday, October 11 with “Buy”. Wedbush maintained the stock with “Outperform” rating in Wednesday, March 22 report. The firm earned “Underperform” rating on Wednesday, June 29 by BMO Capital Markets. The rating was maintained by Canaccord Genuity on Monday, January 29 with “Hold”.

It closed at $36.1 lastly. It is down 12.40% since February 15, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.08 EPS, up 33.33 % or $0.04 from last year’s $-0.12 per share. After $-0.11 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.47 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

More important recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Prnewswire.com which released: “What’s Happening With These Generic Drugs Stocks? — Neos Therapeutics, Pacira …” on February 14, 2018, also Globenewswire.com published article titled: “FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL …”, Nasdaq.com published: “Oversold Conditions For Pacira Pharmaceuticals (PCRX)” on January 18, 2018. More interesting news about Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was released by: Nasdaq.com and their article: “Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.